Clinical trials
Viral Infection clinical trials
Below are recruiting viral infection clinical trials, each written for real people, not researchers. We’re tracking 99 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05536219Recruiting
Study how autoantibodies affect virus levels in severe lung infections
This study measures blood immune “autoantibodies” that may affect how much virus is in the body during severe respiratory infections. It may help doctors understand which patients are more likely to have higher virus levels and could guide future treatment choices.
Bron, RhoneAges Any age - NCT04098315Recruiting
HIV drug-resistance patient registry study for people 14+
This study is a registry (a way to collect and organize information) for people living with HIV who have drug-resistant virus. It may help researchers better understand how resistant HIV behaves and how to manage treatment over time.
Milan, MIAges 14 years+ - NCT07125235Recruiting
Support program for HIV treatment adherence
This trial tests a program to help people with HIV stay on track with their medication. If you take HIV medication, sometimes miss doses, and use stimulants, this program may offer support to improve your health.
San Francisco, CaliforniaAges 18–70 - NCT06370780Recruiting
Smartphone app to help with HIV viral suppression
This study uses a smartphone app to help people with HIV who have trouble staying virally suppressed stay healthy. It’s for those who are not currently suppressed, not in care, or at risk of becoming unsuppressed.
Los Angeles, CaliforniaAges 18 years+ - NCT06788093Recruiting
Reducing antibiotic overuse with decision support
This trial tests a tool to help doctors decide when antibiotics are truly needed for lung infections like bronchitis or pneumonia. It may help you avoid unnecessary antibiotics and their side effects.
Oakland, CaliforniaAges 6 months–17 years - NCT03266640RecruitingPhase 2
CMV cell therapy for difficult-to-treat viral infection
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
Los Angeles, CaliforniaAges 1 month–79 years - NCT06206564RecruitingPhase 2
Artesunate ointment for anal precancer in HIV-negative adults
This trial tests an artesunate ointment to treat high-grade anal precancer (HSIL) in people who do not have HIV. The goal is to see if the ointment can clear the abnormal cells caused by HPV.
Chicago, IllinoisAges 18 years+ - NCT05195450Recruiting
Tenofovir to stop liver disease in mild hepatitis B
This trial tests tenofovir alafenamide (a hepatitis B antiviral medicine) to see if it can prevent liver disease from getting worse in people with chronic hepatitis B who currently have stable (normal) liver blood tests and low virus levels. It may help lower the chance of developing serious liver complications over time.
New Delhi, National Capital Territory of DelhiAges 18–70 - NCT05784038Recruiting
Study of monkeypox infection in Brazil
This is an observational study that follows people with confirmed monkeypox (mpox) to better understand the illness over time. It may help doctors learn what to expect and improve care, but it does not test a new treatment.
Belém, ParáAges 18 years+ - NCT05943548Recruiting
Traditional healer support to help HIV reach low viral levels
This study tests whether support from traditional healers can help people with HIV get their viral load down to very low levels. You may be offered additional support and asked to attend clinic and nurse visits over 2 years.
MbararaAges 18 years+ - NCT06909110RecruitingPhase 1/Phase 2
Immune cells for viral infections after transplant
This trial tests a treatment using specially trained immune cells (virus-specific T-cells) to fight stubborn infections with adenovirus, CMV, or EBV in people with weakened immune systems, such as after a stem cell or organ transplant.
Palo Alto, CaliforniaAges 1 month–65 years - NCT06892015Recruiting
Oropouche virus shedding and immune response study
This study monitors how long the Oropouche virus stays in the body and how the immune system responds after a positive diagnosis. It may help us better understand the course of the infection and improve patient care.
Negrar, VRAges 18 years+ - NCT06027879Enrolling by invitationPhase 1/Phase 2
Anti-viral T-cell therapy for stubborn viral infections after transplant
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
Pittsburgh, PennsylvaniaAges 1 month–65 years - NCT06507059RecruitingPhase 3
Injectable HIV treatment trial for people with unsuppressed virus
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
KeelungAges 18 years+ - NCT06886971Recruiting
Strategies to help youth with HIV stay virally suppressed
This trial tests a strategy to help young people with HIV keep their virus levels low. It focuses on using a long-acting injectable medication combination (Cabotegravir and Rilpivirine) and requires communication with your HIV doctor.
Baltimore, MarylandAges 12–30 - NCT05664126RecruitingPhase 2
Donor immune-cell treatment for stubborn CMV or adenovirus after transplant
This trial tests virus-fighting immune cells (T-cells) made from a donor to treat stubborn CMV or adenovirus infections after a blood and bone marrow transplant. It may help clear the virus when standard antiviral medicines are not working.
Memphis, TennesseeAges Up to 18 years - NCT05866952Recruiting
Breathing and blood-flow testing in long-COVID symptoms
This trial studies how the lungs’ breathing (airflow) and blood flow may be off in people with long-COVID symptoms like tiredness, shortness of breath, or trouble exercising. It may help researchers understand what’s driving symptoms and what kinds of abnormalities could be targeted.
Boston, MassachusettsAges 18–99 - NCT06267508Recruiting
HIV testing and treatment for newborns
This study looks at ways to test and treat newborns for HIV early to improve their long-term health. It is for mothers with HIV whose babies are less than 3 days old and who are willing to have their babies tested and followed at home.
BeiraAges 18 years+ - NCT05534425Enrolling by invitation
Study of a community mentoring program to boost antiviral defenses
This study tests whether a community-based, intergenerational mentoring program can help the body’s natural defenses against viruses. You may be able to join if you’re part of the GenX program and meet the basic location and screening requirements.
Los Angeles, CaliforniaAges 50 years+ - NCT05564598RecruitingPhase 2
Trial of immune therapy for newborns with congenital CMV
This Phase 2 trial tests an immune treatment made from donor T-cells to help the body fight congenital CMV infection in newborns. It may be an option if your baby is very young, has evidence of CMV infection, and meets specific blood, kidney, and liver safety limits.
Los Angeles, CaliforniaAges birth–3 weeks - NCT06070688Recruiting
A test to tell if your breathing infection is bacterial or viral
This study tests a new way to quickly figure out if a respiratory infection is caused by bacteria or a virus. Knowing this could help doctors choose the right treatment faster and avoid unnecessary antibiotics.
Houston, TexasAges 18 years+ - NCT05918510Recruiting
Blood and tumor study for virus markers in throat cancer
This study looks at virus-related markers and tiny gene regulators (microRNAs) in tumor tissue from people with certain throat cancers caused by human papilloma virus (HPV). It’s observational, meaning it does not change your treatment, but results may help doctors better understand these cancers and how they behave.
RomeAges 18 years+ - NCT04098744RecruitingPhase 2
Artesunate vaginal inserts for high-grade cervical changes
This Phase 2 study tests whether artesunate vaginal inserts can help treat high-grade abnormal cells on the cervix (CIN2/3). It’s meant for adults who have a confirmed high-grade precancer change and can use birth control during the study.
Fort Myers, FloridaAges 25–100 - NCT05361603Recruiting
Screening for hepatitis B, C, and HIV at the same time
This trial tests how acceptable it is for people who use services outside traditional clinics to be screened for hepatitis B, hepatitis C, and HIV during the same visit. If you join, you would be asked to participate and provide consent for the screening process.
Limoges, Haute VienneAges 18 years+
Hear when a new Viral Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for viral infection?
- Yes. Clin2 currently lists 99 recruiting viral infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a viral infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a viral infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.